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Regulation of human cortical
interneuron development
by the chromatin remodeling
protein CHD2
E. M. A. Lewis1,2, G. Chapman1,2, K. Kaushik1, J. Determan1, I. Antony1, K. Meganathan1,
M. Narasimhan1, P. Gontarz1, B. Zhang1 & K. L. Kroll1*
Mutations in the chromodomain helicase DNA binding protein 2 (CHD2) gene are associated with
neurodevelopmental disorders. However, mechanisms by which CHD2 regulates human brain
development remain largely uncharacterized. Here, we used a human embryonic stem cell model of
cortical interneuron (hcIN) development to elucidate its roles in this process. We identified genomewide CHD2 binding profiles during hcIN differentiation, defining direct CHD2 targets related to
neurogenesis in hcIN progenitors and to neuronal function in hcINs. CHD2 bound sites were frequently
coenriched with histone H3 lysine 27 acetylation (H3K27ac) and associated with high gene expression,
indicating roles for CHD2 in promoting gene expression during hcIN development. Binding sites for
different classes of transcription factors were enriched at CHD2 bound regions during differentiation,
suggesting transcription factors that may cooperatively regulate stage-specific gene expression with
CHD2. We also demonstrated that CHD2 haploinsufficiency altered CHD2 and H3K27ac coenrichment
on chromatin and expression of associated genes, decreasing acetylation and expression of cell
cycle genes while increasing acetylation and expression of neuronal genes, to cause precocious
differentiation. Together, these data describe CHD2 direct targets and mechanisms by which CHD2
prevents precocious hcIN differentiation, which are likely to be disrupted by pathogenic CHD2
mutation to cause neurodevelopmental disorders.
Disruption of the processes that regulate fetal brain development can contribute to the etiology of neurodevelopmental disorders (NDDs), including autism spectrum disorder (ASD) and epileptic encephalopathies, the
latter of which are a group of pediatric onset epilepsies with poor p
 rognoses1–3. Many of these disorders arise,
at least in part, from altered development of excitatory and inhibitory neurons in the cerebral cortex, where
GABAergic cortical interneurons (hcINs) and glutamatergic excitatory projection neurons normally interact to
modulate the balance of excitatory and inhibitory neuronal inputs to enable proper cortical function4–6. Transcription factors (TFs) and chromatin modifying proteins act together to control gene regulatory networks that
underlie the specification and differentiation of both hcINs and cortical excitatory neurons. Mutations in genes
encoding chromatin modifying proteins are over-represented among pathogenic contributors to NDDs, further
demonstrating the critical nature of these proteins during neurodevelopment7–9. However, there is little known
about the role of many of these proteins in and how their mutation alters neurodevelopment.
CHD2 is part of the nine-member chromodomain helicase DNA-binding (CHD) family of chromatin remodeling proteins. CHD family proteins are involved in a range of developmental processes, while mutations in
several CHD family members cause human diseases including NDDs10,11. These proteins all contain chromodomains, which mediate their association with chromatin, and ATP-dependent helicase domains, which can
remodel nucleosomes, while CHD1 and CHD2 also contain domains for direct binding to D
 NA11,12.
While the direct targets of CHD2 and mechanisms of action during brain development remain unknown,
CHD2 has been shown to co-bind the genome together with cell type-specific transcription factors, including
MyoD during myocyte differentiation13 and OCT3/4 in mouse embryonic stem cells14. Likewise, in our prior
work we showed that CHD2 could co-bind the genome with the homeodomain transcription factor NKX2.1 at
several target genes during specification of human ESCs (hESCs) to medial ganglionic eminence-like progenitors
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(hMGEs) and during their differentiation into hcINs15. CHD2 has also been shown to enhance deposition of the
variant histone H3.3; which is associated with hyperdynamic chromatin enrichment at the promoter of genes
that regulate cell-type specific developmental programs13,14,16,17, and is generally associated with poised or active
histone modifications14,17. Finally, in addition to roles in regulating chromatin state to control gene expression,
CHD2 has also been shown to modulate DNA damage repair by increasing nucleosome spacing and interaction
with PARP1, potentially via promoting H3.3 incorporation into n
 ucleosomes18.
Requirements for CHD2 activity during brain development have been studied in other developmental contexts, primarily in mouse models. Two CHD2 deficient mouse models displayed evidence of abnormal neural
development although, similar to prior work in human cellular models, neither recapitulated a human epilepsy
phenotype16,19. Other studies characterizing mouse models of CHD2 deficiency did not report neurological
abnormalities and instead identified spinal, blood, and renal a bnormalities2,20–22. We also previously demonstrated
delayed maturation of hESC-derived human cortical interneurons following either shRNA-based knockdown of
CHD2 or CRISPR-based biallelic CHD2 knockout, with these hcINs exhibiting subsequent electrophysiological abnormalities, while human cortical excitatory neurons displayed no electrophysiological a bnormalities15.
Building upon these studies, we sought to elucidate the role of and mechanisms by which CHD2 regulates
hcIN development. To do this, we first defined genomic locations bound by CHD2 during hESC specification into
hMGE progenitors and their subsequent differentiation into hcINs, as well as examining corresponding changes
in chromatin state at these regions during specification and differentiation. To understand requirements for
CHD2 action we also manipulated CHD2 expression, generating an hESC line with heterozygous CHD2 mutation, which mimics the haploinsufficiency seen in many patients heterozygous for pathogenic CHD2 mutation
or deletion. This work revealed cis-sequence features underlying CHD2 binding, chromatin state changes that
occurred at these locations during differentiation, and key aspects of these developmental programs that were
disrupted by CHD2 haploinsufficiency. Together, our work here has defined direct targets and mechanisms of
action by which CHD2 controls hcIN development and has determined how these are disrupted under conditions
of CHD2 haploinsufficiency, providing a framework for understanding why the CHD2 gene is among those least
tolerant to sequence variation in the human g enome3.

Results

Expression of genes associated with CHD2 binding during hcIN differentiation. To understand
how CHD2 might regulate hcIN differentiation, we assessed its genome-wide binding profile at day 0 (in hESCs),
day 15 (in hMGEs), and day 35 (in hcINs) (Fig. 1A; Table S1), observing more peaks in hESCs (42,707), by
comparison with hMGEs (19,626), or hcINs (17,737) (Fig. 1B). To assess how CHD2 peak locations changed
during hcIN specification and differentiation, peaks were divided into those unique to one time point or present
(shared) at two or more time points. Almost half of all hESC peaks (26,980) were unique to this time point. A
similarly large number of peaks (10,946) were shared between all three cell states profiled, while smaller numbers of peaks were unique to hMGEs (4737) or hcINs (3105) (Fig. 1B). These peaks may be associated with roles
that CHD2 performs specifically during hMGE specification or hcIN differentiation.
Since regulatory proteins often bind both promoter-proximal and distal regulatory elements, we next investigated genomic annotations of CHD2-bound regions. During specification and differentiation, we found no
major differences between annotations of CHD2 bound peaks, with a large number being either in introns or
intergenic space, some of which may overlap cis-regulatory elements, while a smaller fraction were at gene
promoters (Fig. 1C).
We hypothesized that stage specific CHD2 binding could be associated with correspondingly increased
expression of the nearest associated gene. To investigate this, we assessed how expression of CHD2-associated
genes changed during differentiation. Using our previously derived RNA-sequencing data for hESCs (day (D)
0), hMGEs (D15), and hcINs (D35) (Table S2), we clustered all genes with a greater than 1.5-fold change in gene
expression either between D0-D15 or between D15–D35, to define 12 clusters of genes with similar expression
profiles (Fig. 1D, Sup. Fig. S1). To validate the use of this clustering approach we examined 3 key markers of
hMGE progenitors (ASCL1, DLX2 and NKX2.1, Sup. Fig. S1), finding that they belonged to cluster 11, which
contains genes that peak at day 15 as was expected for these hMGE markers. We also examined 3 key markers
of hcINs (SST, GAD1 and GAD2, Sup. Fig. S1) and found that they were assigned to cluster 9, which showed
increased expression across differentiation as was expected for hcIN markers.
To focus on the highest-confidence regulatory element-to-gene associations, we focused on CHD2 peaks
within 2 kb up- or downstream of the transcription start site (TSS; Table S1) and those peaks bound by CHD2
only at one stage (e.g. CHD2 bound uniquely in hESCs, but not in hMGEs or hcINs) and identified the expression cluster corresponding to each CHD2-associated gene. The enriched expression clusters differed, depending upon the stage of CHD2 binding examined. For example, CHD2 bound genes in hESCs were enriched for
clusters 4 (dark green), 6 (red), and 8 (orange), each of which show decreased expression from D0-D15, during
hESC pluripotency exit and hMGE specification (Fig. 1D,E). By contrast, CHD2 bound genes in hMGEs and
hcINs were enriched for expression clusters 1 (light blue), 2 (dark blue), 3 (light green), 9 (light purple) and 11
(yellow), all of which increase in expression during hMGE specification and hcIN differentiation (Fig. 1D,E).
Examples of the CHD2 binding and expression profiles for genes in some of these clusters are shown (Fig. 1F–H).
These findings support our hypothesis that temporally restricted CHD2 binding during hcIN differentiation is
associated with increased gene expression.
CHD2 associates with suites of genes involved in stage‑related developmental processes. To
explore the identity of these CHD2-associated genes, we next performed gene enrichment analysis. Specifically,
genes associated with at least one CHD2 bound peak that was proximal to the promoter and only bound at one
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Figure 1.  Genome-wide interrogation of CHD2 binding during hcIN differentiation from hESCs. (A)
Differentiation scheme used to produce human cortical interneurons (hcINs) from human embryonic stem cells
(hESCs) in vitro. Samples were collected and analyzed at day 0 (D0, hESCs), day 15 (D15; medial ganglionic
eminence-like progenitors, hMGEs), and day 35 (D35, hcINs). (B) Number of peaks bound by CHD2 at each
time point assayed, including stage-specific ’unique’ peaks (D0, D15, and D35) and peaks present at multiple
time points. (C) Genomic annotation of CHD2 bound peaks identified in hESCs, hMGEs, and hcINs, for all
peaks present at each cell stage. (D) Examples of gene expression during differentiation of wild type (WT)
hESCs into hcINs. 12 gene expression profile clusters were generated, with all genes in each cluster having
similar expression trends; each example expression profile represented here corresponds to the cluster centroid
values, assuming a D0 RPKM value of 1. (E) Distribution of genes with stage-specific, ‘unique’ CHD2 binding at
the promotor region across the 12 WT gene expression clusters. (F–H) Epigenome Browser views for example
genes in cluster 4 (F, NANOG), 11 (G, LHX2) and 9 (H, SYN5), showing RNA expression and CHD2 binding
from hESC (D0) to hcIN (D35). Promoter proximal CHD2 peaks are indicated as yellow highlights.

stage (i.e. hESC, hMGE, or hcIN ’unique’ peaks) were used for analysis. Terms associated with genes with hESCunique CHD2 bound peaks included ‘cell–cell signaling’ and ‘morphogenesis’ (Fig. 2A,B, Table S3). Genes with
at least one CHD2-associated peak unique to hMGEs or hcINs were instead predominantly associated with
terms related to neurodevelopment (Fig. 2C–F, Table S3). For example, terms associated with hMGE-unique
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CHD2 peaks included ‘neurogenesis’ (Fig. 2C,D, Table S3), while terms associated with hcIN-unique CHD2
peaks were associated with more mature neurons, including ‘voltage-gated cation channel activity’ and ‘neuron
projection development’ (Fig. 2E,F; Table S3). By comparison with these stage-specific binding events, terms
associated with ‘all’ peaks (shared or unique) bound by CHD2 in hMGEs or hcINs were associated with similar
processes, but the associations were less pronounced (Table S3).
Pathogenic mutation of CHD2 is known to contribute to NDDs, including ASD and epilepsy, while many
ASD- and epilepsy-associated genes are likewise important for neural development and neuronal function. We
therefore compared genes that were bound by CHD2 at each developmental time point in our experimental
scheme with known ASD and epilepsy genes. From a list of 102 ASD risk-associated genes23, 53 (52%) were bound
by CHD2 at some point during hcIN differentiation, while many (34) of these genes were bound by CHD2 in
hESCs, hMGEs, and hcINs (Supplemental Fig. S2; ASD). Most of these genes had low expression in hESCs and
were highly expressed in hcINs, congruent with the involvement of many ASD-associated genes in neuronal
differentiation or maturation (Supplemental Fig. S2). In comparisons with 536 epilepsy-related g enes24, 57 (11%)
were also bound by CHD2 at some point during hcIN differentiation, and many (32) of these were likewise CHD2
bound in hESCs, hMGEs, and hcINs (Supplemental Fig. S2; Epilepsy).
We next performed network analysis of the genes associated with CHD2 peaks unique to hESCs, hMGEs,
or hcINs. Themes output from this analysis were congruent with the previously identified GO terms (Table S3),
and one representative high-scoring theme for each stage of differentiation was selected for further analysis. For
CHD2 bound genes in hESCs, a major theme was related to intracellular junctions and epithelial identity, and
included genes such as MARVELD2/3, CLDN7/10/19, and CDH1/6 (Fig. 2G). For CHD2 bound genes in hMGEs,
this theme was related to neuroectoderm development and included genes such as GBX2, SMAD2/4, ZIC1/3,
and BMP7 (Supplemental Fig. S3). For CHD2 bound genes in hcINs, this theme was related to synapses, and
included genes such as CHRNA4, SLC17A7, NPAS4, and CNTN2 (Fig. 2H). Together, this indicates that CHD2
may be involved with maintaining proper expression of genes required for cell adhesion and cell cycle progression during the transition from pluripotency through early neural fate acquisition, as well as those required for
later neuronal specification, differentiation, and maturation, further confirming a relationship between the stage
of CHD2 binding and expression and activity of the associated genes.

CHD2 peaks in hMGEs and hcINs contain binding motifs for transcription factors associated
with hcIN development. Since CHD2 can co-regulate gene expression with cell type-specific transcrip-

tion factors (TFs)13–15, we next explored the sequence enrichment for TF binding sites (TFBSs) under CHD2
peaks. As in prior analyses, we focused on CHD2-bound peaks that were bound in a stage-specific manner
(“unique” peaks, including all peaks regardless of the distance to the nearest TSS), as these may represent regulatory elements specific to aspects of hcIN specification or differentiation. At the hESC stage, a range of TFBS
were present at unique CHD2 binding sites (Fig. 3A, Table S4). Many of these transcription factors (e.g. OCT4,
NANOG, and ZIC3) play roles in pluripotency and are highly expressed in hESCs.
At the hMGE stage, CHD2 bound sites continued to be enriched for TEAD binding motifs (Fig. 3B, Table S4);
correspondingly, TEAD factors were highly expressed at both the hESC and hMGE stages (Supplemental Fig. S4;
TEAD). CHD2 peaks specific to hMGE progenitors were also enriched for a number of homeodomain TFBS
including those recognized by LHX2, DLX2, and NKX2.1, all of which play roles in hcIN development (Fig. 3B,
Table S4). To further examine the potential relevance of these TFBS, we assessed the relative expression of all
TFs from D0 to D15 of differentiation and annotated a subset of TFs that exhibited increased expression at
D15 relative to D0 (Fig. 3D, Table S5). This analysis further highlighted multiple homeodomain TFs identified
by the TFBS analysis, including NKX2.1, DLX1, SIX6 and LHX2, while further examination demonstrated
that expression of many of these TFs is highest in hMGEs, relative to hESCs and hcINs (Supplemental Fig. S4;
Homeodomain). These results suggest that CHD2 binding is associated with sites for binding by TFs that are
important to specify hMGE progenitors.
Performing a similar TFBS analysis at the hcIN stage demonstrated enrichment for homeodomain, basic helix
loop helix (bHLH), and Regulatory Factor binding to the X-box (RFX) TF binding motifs (Fig. 3C, Table S4). We
found that, while many of these TFs were highly expressed at D35 (Fig. 3E, Table S5), their expression increased
the most strongly from D0-D15 and then continued to increase D15–D35, suggesting roles in both specification
and differentiation of hcINs (Fig. 3D,E, Supplemental Fig. S4, Table S5). Together, these data suggest that CHD2
may work with a range of TFs known to regulate the development of neurons or specifically cortical interneurons.

CHD2 binding coenriches with H3K27ac in differentiating hcINs. After determining that CHD2 is

frequently associated with genes with increasing expression during hcIN differentiation and is likely to co-localize at these sites with TFs that play important roles in this process, we next assessed the chromatin state of these
putative regulatory elements. Since CHD2 has been shown to associate with poised or active chromatin14,17, we
investigated three histone modifications associated with establishing these chromatin states: H3K4me3, which
is enriched at active or bivalent promoters, H3K27me3, which enriches at repressive chromatin and bivalent
promoters, and H3K27ac, which enriches at active enhancers.
By comparison with their chromatin state in hESCs, CHD2-bound, promoter-proximal (+/− 2 kb from the
TSS) genomic regions exhibited increased H3K27ac coenrichment during hMGE specification and hcIN differentiation (Fig. 4A, Table S1). The peak subset that bound CHD2 in hMGEs and/or hcINs, but not in hESCs,
showed the most pronounced CHD2 and H3K27ac coenrichment (Fig. 4A, Table S1). In examining all promoterproximal genomic regions to which CHD2 binds in a non-temporally specific manner we also observed coenrichment with H3K4me3 at the hMGE stage and with H3K27ac at the hcIN stage, further suggesting an association
between CHD2 binding and histone modifications associated with gene expression (Supplemental Fig. S5A).
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Figure 2.  Analysis of genes associated with CHD2 binding during hcIN differentiation. (A–F) Gene ontology
(GO) enrichment analysis of genes with a promoter proximal CHD2 peak uniquely in (A, B) hESCs, (C, D)
hMGEs, or (E, F) hcINs. − Log10 p values for top enriched terms are shown. (G, H) Gene networks generated
from a single representative GO term. In (G), the hESC ‘unique’ CHD2-bound gene network was generated
by focusing on intracellular junction-related genes. In (H), the hcIN ‘unique’ CHD2-bound gene network was
generated by focusing on synapse-related genes.
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Figure 3.  Analysis of candidate TFs that may co-bind the genome with CHD2 during hcIN differentiation.
(A–C) Predicted transcription factor (TF) binding motifs under CHD2 peaks unique to (A) hESCs, (B)
hMGEs and (C) hcINs. Adjusted p-values, the percentage of peaks with each TFBS, and the TF class are shown
(HD = homeodomain, ZF = Zinc finger, FH = forkhead). (D) Expression changes of up-regulated TFs from hESC
(D0) to hMGE (D15). Only TFs with a RPKM value greater than 1 (i.e. log2 RPKM > 0) and a positive fold
change from D0 to D15 (i.e. log2 FC > 0) are shown. (E) Expression changes of up-regulated TFs from hMGE
(D15) to hcIN (D35). Only TFs with a RPKM value greater than 1 (i.e. log2 RPKM > 0) and a positive fold
change from D15 to D35 (i.e. log2 FC > 0) are shown.
To further examine the role of CHD2 binding in hcIN development we analyzed the chromatin state of all
peaks (not just promoter-proximal) that were bound by CHD2 either uniquely in hESCs (Fig. 4B, Table S1) or in
hMGEs and/or hcINs, but not hESCs (Fig. 4C, Table S1). Peaks uniquely bound by CHD2 in hESCs were most
highly enriched for active histone modifications (H3K27ac or H3K4me3) in hESCs (Fig. 4B, D0), with a subset
of these sites losing these active histone marks and/or gaining H3K27me3 during later stages of development.
Peaks bound uniquely by CHD2 in hMGEs/hcINs instead coenriched predominantly for H3K27ac during differentiation (Fig. 4C; D15 and/or D35), having substantially less coenrichment with any histone marks at the
hESC stage. However, it is important to note that, while both hESC-unique and hMGE/hcIN unique CHD2
peaks are generally enriched for H3K4me3 at the time of CHD2 binding, many of these peaks are coenriched for
H3K4me3 during all stages of development (Fig. 4B,C D0/D15/D35). This trend is even more pronounced when
examining sites where CHD2 is bound throughout development (Supplemental Fig. S5B, Table S1), suggesting
that H3K4me3 coenrichment does not temporally relate to CHD2 binding or activity.
We also observed an increase in coenrichment of CHD2 with bivalent chromatin (carrying co-localized
H3K27me3 and H3K4me3) at later stages of development, both at sites that are bound uniquely by CHD2 in
hESCs and in hMGE/hcINs (Fig. 4B,C; D15 and/or D35). Examining all the sites of CHD2 peak coenrichment
with bivalent chromatin, most of these sites were enriched for H3K4me3 at D0 and then gained the repressive
H3K27me3 mark to become bivalent during differentiation (Fig. 4A, Supplemental Fig. S5C). This transition was
more prevalent among the hESC-unique CHD2 peaks, suggesting that the gain of bivalency during differentiation
involves a loss of CHD2 binding and a corresponding gain of the H3K27me3 mark (Fig. 4B,C; D15 and/or D35).
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Figure 4.  Histone modification states associated with CHD2 binding during hcIN differentiation. (A) Signal enrichment of
H3K4me3, H3K27ac, and H3K27me3 modification around CHD2 bound peaks in hESCs, hMGEs, and hcINs. Line plots at top:
averaged signal for CHD2 binding and histone modification in the hESC unique CHD2 peak cluster (upper panels) and the hMGE/
hcIN unique peak cluster (lower panels), respectively. (B, C) Coenrichment of histone modifications with CHD2 bound peaks. For
CHD2-bound peaks that were (B) unique to hESCs or (C) unique to hMGEs and/or hcINs but not hESCs, the number of unique
overlapping peaks for each histone modification at the time indicated in days (D) is shown. Bivalent status was defined by the
intersection between H3K4me3 and H3K27me3 peaks. (D–F) Gene ontology (GO) enrichment analysis of genes associated with
CHD2 peaks unique to hESCs and enriched for (D) H3K27ac at D0, (E) H3K4me3 at D0, or (F) H3K27me3 at either/or D15 or D35.
(G) Gene ontology (GO) enrichment analysis of genes with a CHD2 peak in hMGEs and/or hcINs and associated with H3K27ac at
either/or D15 or D35, with p-values for top terms (expressed as -log10) shown. (H–J) Transcription factor binding site enrichment
under CHD2 peaks unique to hESCs and enriched for (H) H3K27ac at D0, (I) H3K4me3 at D0, or (J) H3K27me3 at either/or D15 or
D35. (K) Transcription factor binding site enrichment under CHD2 peaks in hMGEs and/or hcINs that were coenriched for H3K27ac
at either/or D15 or D35.
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Together, these findings support a model where CHD2 binding is associated with active regulatory elements and
could contribute to maintaining an open/active chromatin state at these sites.
To gain a better understanding of which genes and pathways were associated with the changes in epigenetic
state associated with CHD2 binding, we analyzed the top gene ontology (GO) terms for genes associated with
subsets of CHD2 bound peaks with different histone modification states. For example, hESC-unique CHD2
bound peaks that coenriched with H3K27ac in hESCs were associated with genes related to neurodevelopment,
including ‘Neuron Differentiation’ and ‘Neurogenesis’ (Fig. 4D, Table S6). By comparison, hESC-unique CHD2
peaks that co-localized with H3K4me3 were associated with general developmental genes, with top terms including ‘Embryonic Organ Development’ and ‘Cell Fate Commitment’ (Fig. 4E, Table S6). We also analyzed genes
that were bound by CHD2 uniquely in hESCs but that gained the repressive H3K27me3 mark during neuronal
differentiation (Fig. 4F, Table S7). The terms associated with these genes were similar to those obtained for the
hESC-unique CHD2-bound peaks that co-localized with H3K4me3 and H3K27ac in hESCs, further suggesting
that loss of CHD2 binding is associated with a transition from an active to a more repressive chromatin state at
suites of developmental genes. CHD2-bound peaks in hMGEs/hcINs that coenriched with K3K27ac were also
associated with genes related to neuronal differentiation; however, these terms were related to later neurodevelopmental processes, such as ‘Axongenesis’ (Fig. 4G, Table S6). Taken together, these results suggest that CHD2
binding is predominantly associated with histone marks denoting open and active chromatin and corresponding
to genes involved in key developmental processes.
Since CHD2-bound peak subsets with different histone modification states were associated with developmentally distinct suites of genes, we also assessed the TFBS enrichment underneath these CHD2 peak subsets.
This revealed distinct classes of TFBS enriched at each CHD2-bound peak subset. hESC-unique CHD2 peaks
which co-localized with H3K27ac in hESCs were enriched for homeodomain and TEAD TFBS, including sites
for OCT4 and TEAD1 (Fig. 4H, Table S7). hESC-unique CHD2 binding which co-localized with H3K4me3
in hESCs was instead associated with TFBS for multiple zinc finger transcription factors, including KLF1 and
KLF3 (Fig. 4I, Table S7). CHD2 peaks that were unique to hESCs and that gained H3K27me3 in hMGEs/hcINs
were also enriched for zinc finger TFBS, including motifs for KLF10 and ZEB2 (Fig. 4J, Table S7). By contrast,
hMGE/hcIN-unique CHD2 peaks that co-localized with H3K27ac in hMGEs/hcINs were enriched for distinct
RFX and homeodomain TFBS, including those recognized by RFX1, RFX2, and LHX2 (Fig. 4K, Table S7). These
results suggest that CHD2 may play several roles in interneuron specification and differentiation, depending on
its co-localization with distinct classes of transcription factors.

CHD2 haploinsufficiency causes precocious differentiation through reduced cell cycle and
increased neuronal gene expression. To further elucidate the mechanistic role of CHD2 during hcIN

differentiation, we assessed how heterozygous CHD2 loss of function affected gene expression and chromatin
state during hMGE specification and hcIN differentiation. For this work, we derived an hESC line with monoallelic disruption of CHD2 (CHD2+/−), modeling the CHD2 haploinsufficiency seen in most patients with CHD2
mutations2,25. The guide RNA (gRNA) used targeted the third exon of CHD2 and created a mutant CHD2 allele
with a two base-pair frameshift, predicted to result in a premature stop codon and a severely shortened protein
(88 amino acids in the mutant, versus 1,829 in the WT protein and containing no known CHD2 functional
domains; Figure S6A). Western blot analysis indicated that CHD2 protein levels in the CHD2+/− hESCs were
reduced by ~ 70% (Figure S6B). As has been demonstrated by our previous work in h
 ESCs15 and by others in
14
mouse ESCs , no differences in pluripotency maintenance or cell proliferation were observed in WT versus
CHD2+/− hESCs and both cell lines were karyotypically normal (Figure S6C).
Analyzing gene expression changes between the CHD2+/− and WT models at the hMGE and hcIN stages
of development showed that the majority of differentially expressed genes (DEGs) were down regulated in the
CHD2+/− versus WT model at both time points (Fig. 5A,B). Using our previously generated gene expression
clustering (Fig. 1D, Supplemental Fig. S1A), we determined which cluster these DEGs belonged to. This analysis
highlighted that, at both the hMGE and hcIN time points, DEGs that were downregulated in the CHD2+/− by
comparison with the WT model (CHD2+/− Down) were enriched for expression clusters 4 (green), 6 (red), and
8 (orange) (Fig. 5C,D, Table S1). During differentiation, all of these clusters show decreased expression from D0
to D15 and an overall decrease in gene expression from D0 to D35 (Fig. 1D). These results indicated that CHD2
deficiency reduced the expression of genes that are normally downregulated during hMGE specification and hcIN
differentiation. Enriched GO terms associated with these genes (Fig. 5E,F, Table S8) were related to early aspects
of neurodevelopment or neural fate acquisition and altered cell–cell interactions (e.g. ‘Neural Tube Formation’,
‘Tissue Morphogenesis’, and ‘Tight Junction Assembly’). We also found a set of CHD2+/− Down DEGs seen only
at the hcIN stage; these were in expression cluster 12 (brown) (Fig. 5D); during differentiation, these genes exhibit
decreased gene expression only between D15–D35, during hcIN differentiation (Fig. 1D). These genes were
highly enriched for GO terms associated with cell division, such as ‘Cell Cycle Progression’ (Fig. 5G, Table S8).
At the hMGE stage, there were very few DEGs up-regulated in the CHD2+/− model by comparison with WT
(CHD2+/− Up); however, significant numbers of CHD2+/− Up genes were detected at the hcIN stage. CHD2+/− Up
DEGs in hcINs predominantly fell into expression clusters 1 (light blue), 2 (blue), 3 (light green), 7 (light
orange), 9 (light purple), and 11 (yellow) (Fig. 5D, Table S1). During hcIN differentiation, all of these clusters
exhibit increased expression at D35 versus D0. GO terms associated with these genes (Fig. 5H, Table S8) were
enriched for terms related to neuronal differentiation and maturation such as ‘Synaptic Signaling’ and ‘Neuron
Differentiation’.
To confirm some findings from the RNA sequencing analysis conducted above, we selected six genes that
were significantly down regulated in the C
 HD2+/− model at D35 and belonged to GO terms related to cell cycle
progression and we performed reverse transcription of RNA and quantitative PCR (RT-qPCR). This analysis
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Figure 5.  Gene expression changes in hMGEs and hcINs with CHD2 haploinsufficiency. (A, B) Gene
expression differences (log2 FC) between wild type (WT) and mutant ( CHD2+/−) in (A) hMGEs and (B) hcINs.
Red: down-regulated genes in the mutant (CHD2+/−); green: up-regulated genes in the mutant (CHD2+/−). (C,
D) Distribution across the 12 previously identified WT gene expression clusters for differentially expressed
genes (DEGs) obtained in WT versus CHD2+/− comparisons at the (C) hMGE and (D) hcIN stage. (E–G) Gene
ontology (GO) enrichment analysis of DEGs down regulated in CHD2+/− compared to WT models at the (E)
hMGE or (F, G) hcIN stage. For hcINs, DEGs that mapped to WT expression (F) clusters 4, 6, 8 and 10, versus
(G) cluster 12 were analyzed separately. (H) Gene ontology (GO) term analysis of DEGs that were upregulated
in the CHD2+/− compared to the WT model at the hcIN stage.

confirmed that all six genes were significantly down regulated in the CHD2+/− model, relative to wildtype (WT)
cINs (Fig. 6A). To assess this phenomenon further, we examined the production of neurons in wildtype versus
CHD2+/− hcIN cultures by staining for Somatostatin (SST), a marker of early born hcINs. We found a significant
reduction in the total number of neurons generated in C
 HD2+/− hcIN cultures, with no change in the overall
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Figure 6.  CHD2 haploinsufficiency alters the efficiency of the proliferation to differentiation transition during
hcIN differentiation. (A) RT-qPCR was used to define the expression in WT and CHD2+/− cultures at D35
of 6 significantly down-regulated DEGs (as obtained by RNA-seq analysis), that are associated with cell cycle
progression. (B) Comparison of the numbers of SST immunopositive hcINs in WT versus C
 HD2+/− cultures,
after plating equivalent numbers of progenitors. Earlier and more efficient differentiation of progenitors resulted
in a reduction in the total number of hcINs generated. n = 3 biological replicate experiments. (C) Representative
images of SST and MAP2 staining in WT and C
 HD2+/− D35 cultures. (D) The percentage of nuclei that were
immunopositive for Ki-67 in the WT versus C
 HD2+/− model at D35 of differentiation were defined. n = 3
biological replicate experiments. (E) Representative images of D35 cells immunostained for Ki-67. Scale
bars = 100 µm. Data is represented as mean ± SEM and was analyzed by Students t-test: **P < 0.01 ***P < 0.001
****P < 0.0001 versus control.

percentage of neurons that were SST immunopositive (Fig. 6B,C; Supplemental Fig. S6D). Immunostaining for
NKX2.1 at day 25 also showed no significant difference in the proportion of immunopositive nuclei between
WT and CHD2+/− models (Supplementary Fig. S6E,F), further suggesting that CHD2 haploinsufficiency does
not affect the specification of cortical interneurons.
To confirm that the loss of hcINs was a result of alteration in the numbers of mitotically cycling cells in our
CHD2+/− model, we performed staining for the cell proliferation marker Ki-67 at D35, finding a significant
reduction in the number of Ki-67 positive cells in the CHD2 haploinsufficiency model (Fig. 6D,E). We hypothesized that the loss of proliferating cells and the corresponding reduction in the number of SST+ hcINs present
in CHD2+/− cultures at D35 of differentiation could result from cells prematurely exiting the cell cycle. To test
this hypothesis we pulsed EdU (5-ethynyl-2′-deoxyuridine) for 2 or 12 h at D22 of differentiation and then
immunostained the cells for EdU at D30. Using this metric, we found no significant differences in the number
of EdU+ cells at D30 (Supplemental Fig. S6G–J). Therefore, we suggest that the reduction in the number of
proliferative cells in CHD2+/− cultures is unlikely to be caused by cells prematurely exciting the cell cycle, but
instead reflects a more complete transition of the cell population from cycling progenitors to immature neurons
by D35. Together, this analysis suggests that CHD2 deficiency may enhance the potential for hcIN differentiation.

Epigenetic consequences of CHD2 haploinsufficiency.

As CHD2 binding at both the hMGE and
hcIN stages was predominantly associated with H3K37ac coenrichment, we hypothesized that the reduction of
CHD2 expression could result in the loss of H3K27ac and a corresponding decrease in expression of the associated genes. To investigate this hypothesis, we defined the H3K27ac peaks in the C
 HD2+/− model at both the
hMGE and hcIN stages. We examined H3K27ac differentially bound regions (DBRs) in CHD2+/− and WT model
comparisons associated with genes that were also bound by CHD2 at any time point. We found no DBRs which
showed increased H3K27ac in C
 HD2+/− hMGEs compared to WT (CHD2+/− Up) and very few DBRs (143 peaks)
with reduced H3K27ac in CHD2+/− hMGEs compared to WT (CHD2+/− Down). By contrast, in hcINs we found
2308 CHD2+/− Down DBRs and a smaller number of CHD2+/− Up DBRs (883 peaks).
As there were very few H3K27ac DBRs at the hMGE stage, and the transition from proliferative hMGE progenitors to differentiated hcINs is a critical stage of hcIN development, we focused on the DBRs in hcINs. We
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mapped H3K27ac DBRs in hcINs to the closest TSS and quantified the number that were associated with a DEG
that changed in the same direction as the DBR in the C
 HD2+/− versus WT comparison. While most DBRs did not
associate with a DEG (Fig. 7A, Table S1), 511 CHD2+/− down DBR peaks were associated with a CHD2+/− down
DEG, while 307 C
 HD2+/− up DBR peaks were associated with a CHD2+/− up DEG. To determine which peaks
could be directly affected by CHD2 deficiency, we also quantified how many of these peak-associated genes
were CHD2 bound in hcINs. Surprisingly, substantially more C
 HD2+/− up DBRs were associated with both a
+/−
CHD2 up DEG and with CHD2 binding in hcINs, relative to the same type of comparison for CHD2+/− down
DBRs, resulting in similar numbers of peaks in each category (195 C
 HD2+/− down DBRs associated with a
+/−
+/−
CHD2 down DEG and with hcIN CHD2 binding, and 231 CHD2 up DBRs associated with a CHD2+/− up
DEG and with hcIN CHD2 binding). Finally, to better understand the role of CHD2, we examined the temporal
nature of the CHD2 binding events at these sites. CHD2+/− down DBRs associated with both C
 HD2+/− down
DEGs and CHD2 binding in hcINs were largely sites where CHD2 was bound throughout development (Fig. 7B
"All", Table S1). By contrast, a substantial proportion of C
 HD2+/− up DBRs associated with a C
 HD2+/− up DEG
and with CHD2 binding in hcINs (~ 40%) were sites where CHD2 only bound at later stages of development
(either at both the hMGE and hcIN stages or uniquely in hcINs, Fig. 7B, Table S1).
We went on to assess the function of DEGs that were associated with H3K27ac DBRs as described above. In
these analyses, GO term enrichment was similar for both C
 HD2+/− down and C
 HD2+/− up data sets and predominantly featured terms related to neurogenesis and neuronal differentiation (Fig. 7C,D, Table S9). However,
examining H3K27ac DBRs that were both associated with an H3K27ac DBRs and were bound by CHD2 in hcINs
(Table S9) yielded enriched GO terms related to those observed in our overall DEG analysis (comparison of
Figs. 5G,H, 7E,F, Table S8). C
 HD2+/− Down DBRs associated with both a C
 HD2+/− Down DEG and with CHD2
binding in hcINs were enriched for terms related to cell cycle progression and cell division (Fig. 7E, example in
Fig. 7G, Table S9). By contrast, CHD2+/− Up DBRs associated with both a CHD2+/− Up DEG and with CHD2
binding in hcINs were enriched for terms related to neuronal differentiation and maturation, including genes
implicated in the etiology of NDDs including autism and epilepsy (Fig. 7F, example in Fig. 7H, Table S9). These
results suggest that CHD2 could play a direct role in both up-regulation of cell cycle and down-regulation of
neuronal genes during hcIN differentiation, with CHD2 deficiency resulting in reduced cell cycle and increased
neuronal gene expression, consistent with an alteration of differentiation timing or potential.
Finally, we examined TF binding site enrichment under H3K27ac DBRs associated both with a DEG and with
hcIN CHD2 binding. C
 HD2+/− Down DBRs that met these criteria were enriched for zinc finger TFBS (Fig. 7I,
Table S10), with the TFs that recognize these sites being most highly expressed at the hESC or hMGE stages. By
contrast, CHD2+/− Up DBRs were enriched for RFX factor binding motifs (Fig. 7J, Table S10), while many RFX
TFs are most highly expressed during later stages of development (hMGE and hcIN). These results suggest that
CHD2 could function cooperatively with zinc finger TFs to promote the expression of cell cycle genes, while it
may instead antagonize the ability of RFX TFs to activate gene expression necessary for neuronal maturation. We
hypothesize that these distinct activities underlie a direct requirement for CHD2-regulated target gene expression
to control differentiation, and that this process is dysregulated under conditions of CHD2 deficiency (Fig. 8).

Discussion

In this study, we obtained genome-wide binding profiles for CHD2 at multiple stages of hcIN differentiation and
integrated these data with both gene expression and chromatin state data, defining roles for CHD2 in human
cortical interneuron development for the first time. We also compared chromatin state and gene expression data
for WT MGEs and hcINs versus those with CHD2 haploinsufficiency, to identify epigenetic mechanisms that
may underlie altered regulation of gene expression resulting from CHD2 deficiency. These results provide insight
into the potential consequences of pathogenic CHD2 mutation.
We first identified CHD2 bound genomic regions in hESCs, hMGEs, and hcINs. Many regions were CHD2
bound only at one time point, reflecting stage-specific roles, while CHD2 binding was frequently associated with
high expression of the corresponding gene and with key stage-specific gene functions. CHD2 binding frequently
preceded increased gene expression, suggesting that it may often facilitate a permissive chromatin environment
that enables other TFs to promote gene expression. We also identified distinct classes of candidate TFs that may
coregulate gene expression with CHD2 at each stage of interneuron differentiation. In hESCs, CHD2 bound
sites were enriched for the zinc finger TFBS ZIC3 and TEAD3, and for OCT4 and NANOG TFBS, all of which
regulate pluripotency26,27. These findings are consistent with a prior demonstration that CHD2 and OCT4 can
cooperatively regulate gene expression in mouse E
 SCs14. In hMGE progenitors, CHD2 bound locations were
instead enriched for multiple homeodomain TFBS, some of which have known roles in MGE s pecification28,29.
Finally, in hcINs, CHD2 bound sites were enriched both for homeodomain TFBS, some of which were also
enriched at CHD2 bound sites in hMGEs, and for bHLH and RFX TFBS. Together, these findings support distinct, stage-specific roles for CHD2 during interneuron specification and differentiation and suggest TFs with
which CHD2 may cooperatively regulate gene expression at each stage.
We further examined patterns of TFBS and histone modification coenrichment at CHD2 peaks. In hESCs, our
results were congruent with previously published work, demonstrating CHD2 enrichment at active promoters
(coenriched for H4K4me3 and H3K27ac) and enhancers (marked by H3K27ac). Similar coenrichment has been
identified previously in several cell types, including hESCs, mouse ESCs, and K562 human lymphoblast cells14,17.
CHD2 and H3K4me3 were also coenriched at hESC-specific CHD2 peaks that gained the repressive H3K27me3
modification during differentiation, after CHD2 binding was lost. These data suggest that loss of CHD2 binding
is permissive for acquiring a more repressive, bivalent chromatin state and is congruent with a prior finding
for mouse ESCs, which suggested that CHD2 binding could block formation of repressive c hromatin14. During
hMGE specification and hcIN differentiation, CHD2 bound sites frequently gained H3K27ac coenrichment,
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◂Figure 7.  Corresponding epigenetic changes and differential gene expression resulting from CHD2

haploinsufficiency in hcINs. (A) Intersection of H3K27ac differentially bound regions (DBRs) and DEGs in
the WT versus C
 HD2+/− comparisons, and of CHD2 binding events in hcINs. DBRs and DEGs were required
to change in the same direction in CHD2+/− versus WT hcINs. (B) Temporal kinetics of CHD2 binding at
H3K27ac DBRs associated with a DEG. The relative frequency with which DBR and DEG associated peaks
were bound by CHD2 throughout differentiation (“All”) was compared was compared with the fraction of
DBR- and DEG-associated peaks bound by CHD2 only at later stages of development (either at both the hMGE
and hcIN stages or uniquely in hcINs). (C, D) Gene ontology (GO) enrichment analysis of DEGs associated
with H3K27ac DBRs that were (C) down-regulated or (D) up-regulated in CHD2+/− hcINs, by comparison
with WT. Top GO terms and their -log10 p-values are shown. (E, F) Gene ontology (GO) term analysis of
DEGs associated with H3K27ac DBRs that were also CHD2 bound in hcINs, where the DEGs and DBRs were
either (E) down-regulated or (F) up-regulated in the CHD2+/− versus WT hcINs. (G, H) Examples of H3K27ac
DBRs that were associated with DEGs and with CHD2 binding in hcINs were obtained from analysis of genes
associated with significant GO terms and include (G) GMMN (down-regulated DBR and DEG in the CHD2+/−
vs. WT comparison) or (H) SYN5 (up-regulated DBR and DEG in the CHD2+/− vs. WT comparison). (I, J)
Analysis of enriched transcription factor binding sites under DBRs that are also CHD2 bound peaks and are
associated with DEGs in hcINs, with analysis considering either sequences under peaks that were (I) downregulated or (J) up-regulated DBRs and DEGs in CHD2+/− versus WT hcINs.

suggesting that this change in chromatin state may be central to CHD2-mediated target regulation during
interneuron differentiation.
Assessing the effects of CHD2 haploinsufficiency provided additional information regarding its roles in
interneuron differentiation. A particularly interesting gene set was down-regulated in C
 HD2+/− hcINs, relative to
WT conditions, and included many cell cycle genes, the expression of which normally decreases in the WT model
only after MGE specification and during hcIN differentiation. By contrast, genes upregulated in C
 HD2+/− hcINs
were largely related to neuronal differentiation and function. Together, these data support a role for CHD2 in
controlling the transition from proliferative hMGE progenitor to post-mitotic hcIN. These results are reminiscent
of findings from prior murine and human studies of CHD2 loss, which resulted in reduced progenitor proliferation and accelerated d
 ifferentiation16,19,30. For example, Shen et al.16 found premature neuron differentiation upon
shRNA-based Chd2 knockdown in mouse cortex. Kim et al.19 also identified reduced cIN progenitor numbers in
the MGE of Chd2+/− mice, resulting in abnormal transcriptomic and electrophysiological properties of mature
cINs. During differentiation of the LUHMES neural progenitor cell line, Lalli et al.30 also showed that CHD2
knockdown reduced progenitor proliferation. Finally our previous work on a CHD2 knock-out hESC model
showed a loss of TUBB3+ cells and reduced expression of both hMGE (LHX6 and DLX2) and mature hcIN
(GAD2) markers15. These results are also consistent with our hypothesis that CHD2 functions to regulate the
transition between mitotically cycling progenitors and maturing hcINs. However, the prior findings additionally
suggested that, either directly or indirectly, the complete loss of CHD2 resulted in functional neuronal alterations, including a significantly lower threshold for action potential firing and larger peak sodium c urrents15.
While prior studies are compatible with our findings here, supporting a role for CHD2 in regulating the
transition of cortical neurons from proliferation to differentiation, the mechanistic basis of this requirement was
previously unknown. Based upon our data, we propose a model for CHD2 function during hcIN differentiation
(Fig. 8). Our data indicates that CHD2 directly regulates two broad classes of genes, those involved in maintaining
hMGE progenitors as proliferative cells (cell cycle genes, Fig. 8) as well as those that promote hcIN differentiation
(neuronal genes, Fig. 8). CHD2 bound sites at cell cycle genes coenrich for H3K27ac and are associated with
genes that are highly expressed in hMGE progenitors, relative to hcINs. CHD2 deficiency causes H3K27ac to
be lost at these sites, while expression of the associated genes decreases. We hypothesize that CHD2 deficiency
reduces the active, open chromatin state (marked by H3K27ac) at these sites, reducing the ability of TFs to bind
and activate cell cycle gene expression (Fig. 8). Conversely, at CHD2 bound neuronal genes, CHD2 deficiency
results in H3K27ac gain at CHD2 peak locations and a corresponding increase in expression of the associated
neuronal gene. We hypothesize that CHD2 binding to peaks associated with these neuronal genes may instead
antagonize the recruitment of TFs such as RFX4, which can activate neuronal gene expression (Fig. 8); therefore, reducing CHD2 levels may indirectly promote neuronal gene expression by facilitating transactivation of
regulatory elements by RFX or other TFs. Together, these data support direct CHD2 requirements at two distinct
classes of target genes to regulate cell cycle and neuronal gene expression, respectively, during hcIN differentiation. Further work to test the predictions of this model, including determining how CHD2 haploinsufficeny or
pathogenic mutation alters its genome binding profile and, consequently, how this alters TF binding and activity at CHD2 peak locations, will provide further insight into the mechanisms by which this regulation occurs.
These results also suggest altered mechanisms by which CHD2 mutations could cause neurodevelopmental
phenotypes. For example, reduced expression of genes that promote neural progenitor proliferation under CHD2
deficient conditions could contribute to the microcephaly seen in ~ 20% of patients with CHD2 mutations2.
This dysregulation could also reduce interneuron numbers, disrupting the balance between cortical excitatory
and inhibitory neuronal activity to contribute to epileptic e ncephalopathy31. Likewise, many neuronal genes
with H3K27ac gain and increased expression under CHD2 deficient conditions are linked to the etiology of
autism and other NDDs, including MYT1L, NRXN3, SLC12A5, and SNAP25 (Supplemental Table S9)32–35. Our
finding here suggesting that CHD2 could potentially antagonize the binding or activity of the RFX TFs is also
particularly interesting, as recent work has linked mutations in RFX genes to neurodevelopmental disorders
and demonstrated that TFBS recognized by the RFX TFs are enriched in cis-regulatory regions of ASD risk
genes36. Together, these data describe a network of direct CHD2-dependent target genes implicated in NDDs,
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Figure 8.  Model for CHD2 function during hcIN differentiation. During hcIN differentiation, CHD2 bound
peaks exhibit high H3K27ac (Ac) and are near promoters enriched for H3K4me3 (Me) in genomic locations
enriched for TFBS recognized by zinc finger TFs, including KLF3. CHD2-bound peaks with this configuration
are associated with genes related to mitosis and cell division (cell cycle genes). Under conditions of CHD2
deficiency (CHD2+/−), H3K27ac is reduced at these sites and expression of the associated cell cycle-related
genes is reduced. CHD2 binds another set of peaks without H3K27ac coenrichment in MGE progenitors. These
are enriched for RFX TFBS and are associated with neuronal genes that are not highly expressed until hcIN
differentiation. Under conditions of CHD2 deficiency, H3K27ac levels increase at these peaks and expression
levels of these genes increase, potentially due to the presence of a chromatin environment permissive for binding
of RFX TFs such as RFX4, which can promote neuronal gene expression. Ultimately, these direct requirements
for CHD2 at two distinct direct target gene subsets results in more efficient differentiation in the C
 HD2+/−
model, due to consequent dysregulation of both cell cycle and neuronal genes.

the regulation of which is likely to be disrupted by many CHD2 pathogenic mutations. Given the link between
CHD2 pathogenic mutation and ASD, our findings here provide a set of candidate cis-regulatory elements under
the direct control of CHD2 that can be used to further investigate functional interplay between CHD2 and the
RFX TFs in regulating neuronal gene expression and how its disruption could contribute to the etiology of ASD
and other neurodevelopmental disorders.
Finally, while CHD2 deficiency may impact hcINs most significantly15,16, it will also be important to further
assess its role in human cortical excitatory neurons, as these play an equally important role in properly balancing neuronal excitation and inhibition. Future work to examine how pathogenic mutations in different CHD2
functional domains alter chromatin binding and activity would contribute to our understanding of mechanisms
of CHD2-dependent gene regulation during neurodevelopment and their perturbation in patients with CHD2
mutations. Individuals with CHD2 mutation exhibit a range of phenotypes and clinical diagnoses, including epilepsy, ASD, or both, as well as varying severity of clinical phenotypes. While this may make linking mechanistic
consequences of different classes of CHD2 mutations to clinical phenotypes challenging, such cross-comparisons
could be very informative. We hypothesize that CHD2’s stage-specific roles, suggested by our work here, and the
potential for CHD2 mutations to differentially affect neurodevelopmental gene regulation could contribute to
the heterogeneity of patient diagnoses, through varying effects on the ability of CHD2 to bind target subsets or
to interact with TFs. This could affect the timing of progenitor proliferation and differentiation in some cases,
while additionally or instead altering control of gene expression required for neuronal maturation or function
in others. The data obtained here regarding CHD2’s direct targets, contextual information related to how CHD2
regulates these targets, and mechanisms by which its deficiency affects hcIN development provides a foundation
for understanding neurodevelopmental gene dysregulation that may underlie patient phenotypes. These findings could ultimately be used to guide the development of targeted therapies that focus on restoring chronically
perturbed pathways and processes, with the potential to ameliorate clinical symptoms.

Methods

Cell culture and differentiation.

Work with hESCs was performed in approval and accordance with our
institutional Embryonic Stem Cell Research Oversight Committee (ESCRO) under protocol #12-002. All hESCs
were maintained under feeder-free conditions on Matrigel (Corning) in mTeSR1 (STEMCELL Technologies)
and all experiments were carried out in H9 hESCs, which were obtained from WiCell Research Institute. Specification of hESCs as MGE progenitors (hMGEs) and differentiation into hcINs was performed using our previously described protocol15. Briefly, EBs were produced either in V-bottom 96-well non-adherent plates or using
AggreWell™800 Microwell Culture Plates (STEMCELL Technologies). hESCs were dissociated with Accutase
(Life Technologies) and 40,000 cells per well were added to V-bottom 96-well non-adherent plates (Corning)
or 1.5 × 106 cells per well on an AggreWell™800 Microwell Culture Plate. For AggreWell™800 Microwell Culture
Plates, EBs were formed in EB formation media (STEMCELL Technologies) for 3 days before differentiation
was started (day (D) 0) by switching to hcIN differentiation media. For V-bottom plates, EBs were formed in
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hcIN differentiation media, which constituted day 0 of differentiation. hcIN differentiation media contained
Neurobasal-A (Life Technologies), B-27 supplement (without Vitamin A; Life Technologies), 10 µM SB-431542
(Tocris Biosciences), 100 nM LDN-193189 (Tocris Biosciences), 1 µM Purmorphamine (Calbiochem), and 2 µM
XAV-939 (Tocris Biosciences). For the first 8 days of differentiation, media also contained 10 µM Y-27632 (Tocris Biosciences). EBs made in V-bottom plates were maintained for 4 days before moving to an orbital shaker set
to 80 rpm, whereas EBs generated using AggreWell™800 Microwell Culture Plates were maintained on an orbital
shaker from D0 of differentiation. On D10 of differentiation, EBs were plated onto Matrigel- and laminin- (5 µg/
mL; Sigma) coated plates. At D15 of differentiation, cells were considered hMGE progenitors and were maintained in hcIN differentiation media supplemented with SB-431542, LDN-193189, Purmorphamine, and XAV939. For terminal differentiation neurospheres were formed from hMGE progenitors using either V-bottom
plates or AggreWell™800 Microwell Culture Plates as previously described, in hcIN differentiation media supplemented with 1 µM Purmorphamine. Neurospheres were maintained for 2 days in the required plates and then
were maintained on an orbital shaker for 2 days at 80 rpm. After 20 days of differentiation, neurospheres were
plated onto Matrigel- and laminin- (5 µg/mL) coated plates or chamber slides and maintained in hcIN differentiation media supplemented with 1 µM Purmorphamine. From day 27–31, DAPT (10 µM; Tocris Biosciences),
ascorbic acid (200 µM; Sigma), and BDNF (20 ng/mL; PeproTech) were added to the media, and from day
31–35, DAPT was replaced with cAMP (200 µM; Sigma). Cells were harvested at days 0 (hESCs), 15 (hMGEs)
and 35 (hcINs) for assays, including RNA-sequencing (RNA-seq), RT-qPCR, ChIP-seq, and CUT&Tag. On D0
and D15, hESCs and hMGEs, respectively, were harvested by dissociation with Accutase, and on day 35, Neural Rosette Selection reagent (STEMCELL Technologies) was used to isolate purified populations of differentiated neurons and remove remaining undifferentiated cells from these cultures, followed by dissociation of the
remaining cells with Accutase, and plating as neuronal monolayers for further culture.

Modeling CHD2 haploinsufficiency.

To model CHD2 haploinsufficiency, a heterozygous mutant
(CHD2+/−) hESC line was constructed by CRISPR-based gene disruption in wild type (WT) H9 hESCs, using
our previously described approach15. Heterozygous CHD2 mutation was validated by Sanger sequencing and all
lines were shown to be karyotypically normal, with testing conducted by the Washington University School of
Medicine Cytogenetics and Molecular Pathology Laboratory.

CUT&Tag. CUT&Tag was performed on WT hESCs (day 0), hMGEs (day 15), and hcINs (day 35) for CHD2
and H3K27me3. The protocols.io V.2. protocol37 was followed, using a minimum of 200,000 cells per sample.
The protein A-Tn5 fusion protein (pA-Tn5) was provided by the laboratory of Steve Henikoff and the antibodies
used were Rat anti-CHD2 (Sigma MABE873) and Rabbit anti-H3K27me3 (Cell Signaling Technology #9733).
Secondary antibodies used were Rabbit anti-Rat IgG (abcam ab6703) and Guinea Pig anti-Rat IgG (AntibodiesOnline ABIN101961). Samples with unique dual-end indexes were pooled in equimolar concentrations and
were sequenced by the Washington University Genome Technology Access Center (GTAC) @MGI on the
NovaSeq-6000 sequencer with the S4 flow cell as 2 × 150 bp paired-end reads at a depth of at least 10 million
(M) reads per sample. Raw reads from CUT&Tag samples were processed by AIAP (v1.1) using human genome
hg38 as a reference to perform read quality control, alignment, quantification, and peak c alling38. Peaks from
replicates were intersected using bedtools intersect peak with options -f 0.25 -F 0.25 -e. Peaks identified as intersecting in 2 or more out of 4 total replicates were defined as reproducible peaks.
ChIP‑seq. ChIP-seq was performed on WT hESCs (day 0), hMGEs (day 15), and hcINs (day 35) for H3K27ac
and H3K4me3 and on the line with heterozygous disruption of CHD2 (CHD2+/−) in hMGEs (day 15), and in
hcINs (day 35) for H3K27ac, as described p
 reviously15. The antibodies used were Rabbit anti-H3K27ac (Millipore 07-360) and Rabbit anti-H3K4me3 (Millipore 07-473). Library preparation and sequencing were performed by GTAC@MGI using the HiSeq3000 sequencer to obtain at least 30 M single end 50 base pair reads per
sample. ChIP-seq data analysis was performed as described p
 reviously15.
RNA‑seq. For comparison of gene expression in WT and CHD2+/− cells during hcIN differentiation, RNA

was collected from hMGEs (day 15) and hcINs (day 35) from 4 biological replicate experiments per sample type,
with WT and C
 HD2+/− cells differentiated in parallel to generate each biological replicate. RNA was collected
and quantified as previously described39. RNA-seq library preparation and Illumina sequencing was performed
by the GTAC using the SMARTer Ultra Low RNA kit (Takara-Clontech) per the manufacturer’s instructions.
Paired-end 150 bp reads were obtained using an Illumina NovaSeq-6000 sequencer with the S4 flow cell, to a
depth of ~ 30 M reads per sample. The transcriptomic data and epigenomic data obtained here was also compared with datasets obtained in our previous w
 ork15 that describes transcriptomic changes accompanying differentiation from hESCs (day 0), to hMGE progenitors (day 15), and during hcIN maturation (day 35).
Raw reads from RNA-seq samples were quality trimmed using cutadapt (v2.4) with options—quality-cutoff = 15,10—minimum-length = 3640. Reads were aligned using STAR (v2.5.4b) using human genome hg38 as a
reference with Gencode V27 annotations41. Reads were quantified at the gene level using featureCounts (v1.6.4)
from the subread package42. For differential expression analysis, gene-level quantification from featureCounts
were normalized to counts per million (CPM) using the CPM function in edgeR in R (v3.6)43. Genes with
expression under 1 CPM in more than half of the samples compared were excluded from analysis. Differential
expression analysis was performed with DESeq2 in negative binomial mode using counts for genes that passed
the 1 CPM cutoff44. A twofold expression change, expression higher than 1 CPM, and a Benjamini and Hochberg
false discovery rate (adjusted p value) of < 0.05 were set as cutoff values for a gene to be considered differentially
expressed.
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Quantitative PCR. RNA was isolated using the NucleoSpin RNA kit (Macherey–Nagel), was quantified
using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific) and 1000 ng was used to make cDNA using
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Equal quantities of cDNA were used
as template for the qPCR using the Applied Biosystem StepOne Plus quantitative PCR system. GAPDH was used
as an endogenous quantitative control and all primers used can be found in Table S11. Data were generated from
4 biological replicate samples, each of which consisted of 3 technical replicates. All statistics were performed by
calclating the relative abundance, and data is presented as fold change by comparison with WT.
Annotation and motif analysis of peak sets.

Peak sets were annotated using the annotatePeaks.pl
function in HOMER2 using human reference hg38 and GENCODE V27 a nnotation45. Promoter regions were
defined as +/- 2kb from the transcription start site. Genes and genomic region annotations associated with peaks
were defined using calls based on the nearest transcription start site (TSS) by HOMER. Motif analysis was performed using the findMotifsGenome.pl function within HOMER2 with hg38 as reference and option -size given.

Data clustering and visualization. Clustering analysis was performed using WT gene expression data
from hESCs (day 0), hMGEs (day 15), and hcINs (day 35). All genes with a fold change of less than 1.5 from
hESCs to hMGEs or from hMGEs to hcIN were eliminated from analysis. Clustering was performed on gene
expression (RPKM) values using the kmeans function in the R statistical package46, with a K value of 12 determined using the elbow method of the sum of squared errors. To generate deepTools plots, representative signal
density bigwig files chosen at random from the replicates and normalized to a depth of 10 M reads by AIAP were
used for visualizations with deepTools (v3.5.0)47. The deepTools signal matrix was generated using selected peak
sets by the computeMatrix function in reference-point mode with options -a 2500 -b 2500 -bs 50—missingDataAsZero—referencePoint center. Plots were generated using the plotHeatmap function with options -zMin
0 -zMax 60 -yMin 0 -yMax 60 for uniform signal density scaling. Heatmaps were created using ClustVis48,
with rows centered and unit variance scaling applied to rows. Rows were clustered using correlation distance
and average linkage. Gene ontology enrichment analysis was done using the ToppFun tool from the ToppGene
suite49 and reporting FDR corrected p-values generated using the probability density function methodology.
Gene network analysis was done using the CompBio tool from the PercayAI p
 latform50, using the 1000 genes
with CHD2 binding closest to the TSS (500 genes upstream and 500 downstream) as input to assess each CHD2
bound gene set. Further network analysis and visualization was done using ClueGO (Cytoscape)51.
Immunofluorescence and Edu staining. Where appropriate, cells were treated with 5 µM Edu for 2 or
12 h at day 20 of differentiation. Cells were fixed in 4% Paraformaldehyde and those that were incubated with
Edu were stained using the Click-iT™ EdU Cell Proliferation Kit for Imaging and Alexa Fluor™ 555 dye (Thermo
Fisher Scientific) as per the manufacturers instructions, after which samples were treated the same as those
that were not incubated with Edu. For immunocytochemistry, cells were blocked using 5% donkey serum and
0.1% Tween20 (Sigma). Primary antibodies were: mouse anti-MAP2 (Millipore Sigma, M1406), rabbit anti-SST
(Peninsula Labs, T-4102), rabbit anti-TTF1 (abcam, ab204411), and rabbit anti-KI67 (abcam, ab16667) and were
added overnight at 4 °C. Cells were washed and incubated with secondary antibodies (donkey anti-mouse 555
and donkey anti-rabbit 488 (ThermoFisher Scientific A-31570 and A-21206, respectively) for 1 h at room temperature. Cells were counterstained using DAPI (1 µg/mL) and mounted using ProLong™ Glass Antifade Mountant (ThermoFisher Scientific). Images were obtained using a spinning-disk confocal microscope (Quorum),
using MetaMorph software and image processing with ImageJ. Quantification was performed using a minimum
of 3 random images (technical replicates) taken from a minimum of 3 independent biological replicates. Quantification was performed using CellProfiler, requiring a minimum of 80% overlap between immunostaining and
DAPI staining for positivity to be registered.
Western blotting.

Protein from WT and CHD2+/− embryonic stem cells was isolated in RIPA buffer and
western blotted to detect CHD2 protein using the Rat anti-CHD2 (Sigma MABE873) antibody. Visualization was
performed by chemiluminescence, CHD2 protein was detected at its predicted molecular weight of 200 kDa, and
CHD2 band intensity was normalized to the GAPDH loading control, detected on the same blot.

Statistical analysis. Where appropriate, statistical analysis was carried out using a combination of GraphPad Prism version 9 (GraphPad Software; La Jolla, CA, USA, available from www.graphpad.com) and RStudio
version 3.5.1 (RStudio: Integrated development environment for R; Boston, MA, USA. Available from www.
rstudio.org). All technical replicates were averaged before statistical analysis and specific statistical tests used
for each data analysis are detailed in the figure legends. The number of separate differentiations used for each
analysis is described in the figure legends as n.

Data availability

All data generated and analyzed during this study are included in this published article, while original unprocessed data is publicly available through the Gene Expression Omnibus (GEO) repository (Superseries
GSE182784). The CHD2+/− hESC line used in this study is available from the investigator by material transfer
agreement with Washington University.
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